Abstract | BACKGROUND: OBJECTIVE: DESIGN: Uncontrolled clinical trial. SETTING: Three tertiary care hospitals. PATIENTS: INTERVENTION: MEASUREMENTS: Probability of response and overall survival were measured. Complete remission was defined as normal blood count for age and sex. Partial remission was defined as independence from transfusion and an absolute neutrophil count greater than 0.5 x 10(9) cells/L without growth factor support. Nonresponders were patients who remained transfusion dependent or died. Relapse was defined as no longer meeting criteria for partial or complete remission. RESULTS: The median time to an absolute neutrophil count of 0.5 x 10(9) cells/L was 49 days. The probability of survival was 84% (95% CI, 59% to 95%) at 24 months. The probability of achieving treatment-free remission was 73% (CI, 51% to 91%) at 24 months, and the probability of achieving complete remission was 65% (CI, 39% to 89%) at 50 months. No responding patients have had relapse or have developed secondary clonal disorders. CONCLUSIONS:
|
Authors | R A Brodsky, L L Sensenbrenner, B D Smith, D Dorr, P J Seaman, S M Lee, J E Karp, I Brodsky, R J Jones |
Journal | Annals of internal medicine
(Ann Intern Med)
Vol. 135
Issue 7
Pg. 477-83
(Oct 02 2001)
ISSN: 0003-4819 [Print] United States |
PMID | 11578150
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anti-Bacterial Agents
- Antiemetics
- Immunosuppressive Agents
- Ondansetron
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Aged
- Anemia, Aplastic
(blood, drug therapy, mortality)
- Anti-Bacterial Agents
(therapeutic use)
- Antiemetics
(therapeutic use)
- Cyclophosphamide
(administration & dosage, adverse effects)
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Hematopoiesis
- Humans
- Immunosuppressive Agents
(administration & dosage, adverse effects)
- Leukocyte Count
- Male
- Middle Aged
- Neutrophils
- Ondansetron
(therapeutic use)
- Pilot Projects
- Platelet Transfusion
- Prospective Studies
- Remission Induction
- Survival Analysis
|